Oliver Gautschi Selected Research

Docetaxel (Taxotere)

1/2020	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
1/2018	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
1/2017	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
1/2017	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
2/2011	Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oliver Gautschi Research Topics

Disease

35	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2023 - 10/2004
34	Neoplasms (Cancer) 10/2023 - 10/2004
24	Lung Neoplasms (Lung Cancer) 06/2023 - 03/2006
9	Adenocarcinoma of Lung 01/2020 - 07/2012
8	Disease Progression 01/2020 - 04/2009
4	Malignant Mesothelioma 12/2023 - 12/2015
4	Carcinoma (Carcinomatosis) 03/2011 - 04/2008
3	Hypertension (High Blood Pressure) 01/2020 - 01/2020
3	Sarcoma (Soft Tissue Sarcoma) 04/2018 - 01/2013
2	Neoplasm Metastasis (Metastasis) 12/2021 - 10/2020
2	Hyponatremia 01/2020 - 01/2020
2	medullary Thyroid cancer 01/2020 - 01/2020
2	Brain Neoplasms (Brain Tumor) 10/2018 - 01/2017
2	Adenocarcinoma 04/2018 - 02/2011
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2018 - 02/2011
2	Nausea 12/2015 - 01/2012
2	Vomiting 12/2015 - 01/2012
2	Mesothelioma 09/2007 - 09/2006
1	Bone Resorption 10/2020
1	Neutropenia 01/2020
1	Febrile Neutropenia 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Diarrhea 01/2020
1	Thyroid Neoplasms (Thyroid Cancer) 01/2020
1	Fibrosarcoma 04/2018
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 02/2018
1	Skin Neoplasms (Skin Cancer) 02/2018
1	Melanoma (Melanoma, Malignant) 02/2018
1	Respiratory Insufficiency (Respiratory Failure) 01/2017
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2017
1	Stroke (Strokes) 01/2017
1	Thymoma (Thymic Carcinoma) 12/2016

Drug/Important Bio-Agent (IBA)

9	ErbB Receptors (EGF Receptor)IBA 09/2023 - 02/2007
8	PlatinumIBA 12/2023 - 03/2006
7	Bevacizumab (Avastin)FDA Link 12/2023 - 12/2012
7	Anaplastic Lymphoma KinaseIBA 01/2020 - 01/2013
7	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2013
6	Pemetrexed (MTA)FDA Link 12/2023 - 03/2011
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2017 - 12/2012
6	CrizotinibIBA 01/2017 - 01/2013
6	src-Family KinasesIBA 01/2017 - 05/2006
5	selpercatinibIBA 10/2023 - 01/2020
5	Docetaxel (Taxotere)FDA Link 01/2020 - 02/2011
5	Biomarkers (Surrogate Marker)IBA 07/2013 - 01/2008
4	LigandsIBA 10/2020 - 02/2014
3	Phosphotransferases (Kinase)IBA 10/2023 - 03/2008
3	Circulating Tumor DNAIBA 09/2023 - 10/2019
3	osimertinibIBA 09/2023 - 04/2021
3	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2017
3	pembrolizumabIBA 07/2021 - 12/2016
3	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 02/2011
3	vandetanib (ZD6474)IBA 01/2020 - 05/2013
3	saracatinibIBA 02/2014 - 04/2008
2	NivolumabIBA 12/2023 - 02/2018
2	B7-H1 AntigenIBA 01/2023 - 07/2021
2	Mitogen-Activated Protein KinasesIBA 01/2022 - 01/2017
2	capmatinibIBA 04/2021 - 01/2020
2	RamucirumabIBA 01/2020 - 01/2018
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020 - 01/2020
2	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2020
2	cabozantinibIBA 01/2020 - 10/2018
2	Cell-Free Nucleic AcidsIBA 10/2019 - 10/2004
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2018 - 10/2018
2	Monoclonal AntibodiesIBA 01/2018 - 09/2007
2	VaccinesIBA 01/2018 - 02/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2015 - 01/2013
2	Gefitinib (Iressa)FDA Link 01/2015 - 01/2013
2	VemurafenibIBA 11/2013 - 10/2012
2	Proteins (Proteins, Gene)FDA Link 01/2013 - 01/2007
2	Aurora KinasesIBA 03/2008 - 09/2006
2	DNA (Deoxyribonucleic Acid)IBA 09/2007 - 10/2004
2	Cyclin D1IBA 01/2007 - 03/2006
1	1-methyl-1-piperidinomethane sulfonateIBA 12/2023
1	IpilimumabIBA 12/2023
1	Protein Isoforms (Isoforms)IBA 06/2023
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	trametinibIBA 12/2021
1	binimetinibIBA 01/2021
1	Zoledronic Acid (Zometa)FDA Link 10/2020
1	Denosumab FDA Link 10/2020
1	NF-kappa B (NF-kB)IBA 10/2020
1	SolventsIBA 01/2020
1	AfatinibIBA 01/2019
1	Sunitinib (Sutent)FDA Link 10/2018
1	human ERBB2 proteinIBA 04/2018
1	Death Domain ReceptorsIBA 02/2018
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	AntibodiesIBA 01/2018
1	Glucose (Dextrose)FDA LinkGeneric 11/2017
1	ponatinibIBA 01/2017
1	ceritinibIBA 01/2017

Therapy/Procedure

28	Therapeutics 06/2023 - 05/2006
14	Drug Therapy (Chemotherapy) 01/2022 - 10/2004
5	Immunotherapy 01/2023 - 02/2008
2	Neoadjuvant Therapy 12/2015 - 09/2015
2	Radiotherapy 12/2015 - 09/2015
1	Salvage Therapy 04/2021
1	Pneumonectomy (Lung Volume Reduction) 12/2015